|
COPYRIGHT 2005 International Medical News Group
Revatio
(sildenafil, Pfizer Inc.)
A phosphodiesterase type 5 (PDE5) inhibitor for treating pulmonary arterial hypertension (WHO group I) to improve exercise ability. The second oral therapy approved for PAH; the first was the endothelial receptor antagonist Tracleer (bosentan). Other treatments come in intravenous, subcutaneous, or inhaled forms. Marketed as Viagra for erectile dysfunction.
* Recommended Dosage: 20 mg three times a day, 4-6 hours apart.
* Special Considerations: Labeling notes that efficacy of Revatio has not been evaluated in patients currently on Tracleer. In the trial that led to approval, Revatio was well tolerated, with side effects that were mostly mild to moderate in...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
